<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23413">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01956513</url>
  </required_header>
  <id_info>
    <org_study_id>Etude ADC</org_study_id>
    <nct_id>NCT01956513</nct_id>
  </id_info>
  <brief_title>Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer</brief_title>
  <acronym>ADC</acronym>
  <official_title>Etude ADC Apport de l'IRM Dans l'évaluation du Coefficient de Diffusion Apparent et prédiction de la réponse à la chimiothérapie néoadjuvante Dans le Cancer du Sein</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to assess the sensitivity and the specificity of the
      variation of apparent diffusion coefficient for prediction, after a course of neoadjuvant
      chemotherapy or after modification of the treatment sequence, the pathological response at
      the end of chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We have finally no financial support and any patients have been included.
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Variation of apparent diffusion coefficient before / after a cycle of neoadjuvant chemotherapy or before / after modification of the treatment sequence and correlated with histologic response</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Assess the Variation of Apparent Diffusion Coefficient</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI (Magnetic resonance imaging)</intervention_name>
    <description>MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 18 years.

          -  Patient suffering from a breast tumor, regardless of the stage and size

          -  Patient requiring neoadjuvant chemotherapy

          -  Patient has the ability to undergo 18F-FDG-PET at baseline, at end of cycle 1 and at
             the end of neoadjuvant treatment before surgery

          -  Compulsory affiliation to a social security system.

          -  Obtaining informed consent in writing, signed and dated.

        Exclusion Criteria:

          -  Patient with cognitive or psychiatric disorders.

          -  Patient deprived of liberty by a court or administrative.

          -  Patient with signs against the achievement of MRI, mammography and ultrasound

          -  Patient metastatic

          -  Patient with prior chemotherapy, radiotherapy and hormone therapy for her breast
             cancer

          -  Pregnant women, current lactation

          -  Patient suffering from uncontrolled diabetes (&gt; 11 mmol / L)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne BAILLY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>March 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADC</keyword>
  <keyword>breast cancer</keyword>
  <keyword>complete pathological response</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
